Using DILIsym to Predict Hepatotoxicity Risk During Pre-clinical Development

Date: July 25 2019
Presenter(s): Paul Michalski, Ph.D, GSK

launch Registration

Time:

7:00 am (PDT)

10:00 am (EDT)

3:00 pm (BST)

4:00 pm (CEST)

5:00 pm (IST)

12:00 am (Beijing)

1:00 am (Tokyo, Seoul)

 

Summary of the Presentation:

DILIsym is a quantitative systems toxicology (QST) model of drug-induced liver injury developed by the DILIsim consortium (now a part of Simulations Plus). DILIsym was primarily developed as a tool to gain mechanistic understanding of clinically observed hepatotoxicity. We recently undertook a proof-of-concept (PoC) study to determine the utility of DILIsym as a screening tool in early pre-clinical development. Here we will give an overview of the DILIsym program and discuss the results of the PoC study, highlighting where DILIsym can provide value as a pre-candidate screening tool, as well as its inherent limitations. The presentation will include practical advice on the steps required to industrialize DILIsym as an in-house screening tool.

 

Speaker's Bio:

Paul Michalski, Ph.D. is an Investigator in the Systems Modeling and Translational Biology group at GlaxoSmithKline. He received his Ph.D. in theoretical condensed matter physics from the University of Pennsylvania, followed by a post-doctoral position at Washington University in St. Louis studying the biophysics of cell motility. He was a post-doctoral fellow at the University of Connecticut’s Center for Cell Analysis and Modeling, where he studied the systems biology of learning and memory and developed novel computational approaches to study meso-scale systems such as membrane-receptor clusters. He was an Associate Computational Scientist at The Jackson Laboratory, where he used computational methods to study the three-dimensional structure of the human genome. He has been at GSK since 2017, where his primary focus is on quantitative systems toxicology (QST) models of hepatotoxicity.